In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 74 for your search:
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  stage II chronic lymphocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345

3.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P30CA015704, P01CA018029, NCT01231412

4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100955, 2012-004225-24, PCI-32765CAN3001, NCT01804686

6.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01220, ALLIANCE A041202, A041202, P30CA014236, U10CA031946, NCT01886872

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0123, 2013-003313-17, NCT01980888

8.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: NCI-2014-00118, ECOG-E1912, E1912, U10CA180820, U10CA021115, NCT02048813

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P30CA015704, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCLL084993, NCT00829647

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2401, NCI-2010-00324, IR-6956, MERCK-PSOC-2401, NCT00918723

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2009-0546, NCT01096992

13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LS1084, NCI-2010-02329, 10-003025, NCT01269385

14.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02675, CDR0000701372, NCCTG-N1087, N1087, U10CA025224, NCT01369849

15.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-001, NCT01416428

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2201, NCT01474681

17.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0249, NCI-2012-01248, NCT01629511

18.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-204, NCT01643603

19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 201303012, NCT01747499

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS048, UMN-0508M72589, UMN-MT2004-24, UMN-2005LS048, NCT00345865

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-407, NCT00410163

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 05149, P01CA030206, CHNMC-05149, CDR0000579136, NCI-2010-01230, NCT00577278

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRC014, Celgene # RV-CLL-PI-0223, NCT00628238

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0213, NCI-2012-01690, NCT00632359
1    
New Search